Another Big Drug Deal: Roche to Buy Biotech Firm InterMune

Sunday, 24 Aug 2014 01:57 PM


  Comment  |
   Contact Us  |
|  A   A  
  Copy Shortlink
Swiss drugmaker Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc. for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

Roche said on Sunday it would pay $74 a share for InterMune, representing a premium of 38 percent to Friday's closing price.

The acquisition, which has been recommended by the boards of both companies, is the largest by Roche since 2009, when it bought out the remaining stake it did not already own in U.S. group Genentech for around $47 billion.

The sale of InterMune will not come as a huge surprise to investors. People familiar with the matter said earlier this month that InterMune was working with financial advisers to evaluate strategic options, due to takeover interest from larger drugmakers.

Adding InterMune to its portfolio will give Roche a promising new drug, pirfenidone, for treating a progressive and ultimately fatal scarring condition of the lungs. Pirfenidone is approved for so-called idiopathic pulmonary fibrosis (IPF) in Europe and Canada and is undergoing U.S. regulatory review.

The deal is a further step by Roche to diversify away from its reliance on cancer drugs, where it is the world leader, by expanding into other disease areas, such as respiratory medicine.

Roche already markets lung drugs Pulmozyme and Xolair in the United States and has other experimental respiratory products in clinical development.

Roche said the transaction was expected to be neutral for its core earnings per share in 2015 but would boost profits from 2016 onwards.

Healthcare companies are merging at a record pace, with year-to-date activity topping $346 billion, compared to $212 billion in the year-ago period, according to Thomson Reuters data.

Recent large deals have included AbbVie Inc.'s $54 billion acquisition of Shire Plc and Medtronic Inc's acquisition of Covidien Plc for $43 billion. AstraZeneca Plc, meanwhile, fended off a $118 billion takeover attempt by Pfizer Inc.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact Us  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Year-End Historical Patterns Point to Further Gains for Stocks

Monday, 24 Nov 2014 20:23 PM

When trying to figure out the stock market's direction for a certain period, it's always interesting to look at the mark . . .

Financial Author Das: Despite Lack of Success, Fed Will Keep Easing

Monday, 24 Nov 2014 20:10 PM

The Federal Reserve's massive easing program hasn't helped the economy much, but that doesn't mean it will shrink much a . . .

Gundlach: Fed May Raise Rates Next Year 'Just to See What Happens'

Monday, 24 Nov 2014 19:49 PM

Ace bond investor Jeffrey Gundlach, CEO of DoubleLine Capital, expects the Federal Reserve to raise interest rates in 20 . . .

Most Commented
Top Stories

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved